Selskabets formål er at drive handel samt hermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 1.7 mia. | 79.5 mio. | 322.5 mio. | 226.1 mio. | 22 | |
CVR: 20830131
Secondary names: LABKEMI DENMARK A/S, MILLIPORE A/S
Previous names: KM 156 A/S, LABKEMI DENMARK A/S, SIGMA-ALDRICH DENMARK ApS
Compared to 1.736 companies in Engroshandel med andre maskiner og andet udstyr
Comparison is based on industry median values
Janecke Stokkebokjær Lundring joined the board
Montserrat Jansa Rodriguez left the board
Janecke Stokkebokjær Lundring joined as ADM. DIR.
Montserrat Jansa Rodriguez left as ADM. DIR.
Companies in the same industry and area
CVR 45848752
CVR 38548905
CVR 12478097
CVR 17198238
CVR 39692635
Merck Life Science A/S demonstrates a solid financial health with a consistent upward trajectory in revenue and profit over the past five years. Revenue increased from 1,008.6 million DKK in 2021 to 1,748.8 million DKK in 2025, while profit rose from 37.7 million DKK to 79.5 million DKK in the same period, indicating strong growth and improving profitability. The company's equity has also shown a positive trend, reaching 226.1 million DKK in 2025, although it experienced a slight dip in 2023. With a growing revenue base and improving profit margins, Merck Life Science A/S is well-positioned within the machinery and equipment wholesale industry, although attention should be paid to maintaining equity levels to support future growth.
AI-generated summary
companydata.dk